Developing a cost-effective method for producing therapeutic antibodies
A high-efficiency, low-cost, single-use purification technology for therapeutic antibody manufacturing
This study is working on a new way to make important medicines called therapeutic antibodies, which help treat cancers and autoimmune diseases, by creating a simpler and cheaper process that could make these treatments more available for patients like you.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Bondwell Technologies LP NIH-funded |
| Lab location | 1 site (College Station, United States) |
| Project ID | NIH-11023075 on NIH RePORTER |
What this research studies
This research focuses on creating a new purification technology for therapeutic antibodies, which are crucial for treating various cancers and autoimmune diseases. The approach involves developing a high-capacity, single-use membrane that simplifies the manufacturing process and reduces costs. By conducting extensive interviews with industry experts and leveraging Phase I and II data, the team aims to produce a minimally viable product that meets industry standards and can be validated by key players in the field. This innovative method could significantly enhance the availability and affordability of antibody-based treatments for patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with cancer or autoimmune diseases who may benefit from antibody-based therapies.
Not a fit: Patients who do not require antibody-based treatments or those with conditions not addressed by these therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more affordable and accessible antibody therapies for patients suffering from cancer and autoimmune diseases.
How similar studies have performed: Previous research has shown promise in developing alternative purification methods for antibodies, indicating that this approach could lead to significant advancements in the field.
Where this research is happening
College Station, United States
- Bondwell Technologies LP — College Station, United States (Active)
Researchers
- Principal investigator: Howell, David W. — Bondwell Technologies LP
- Study coordinator: Howell, David W.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.